Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin America. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksValiRx Regulatory News (VAL)

Share Price Information for ValiRx (VAL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 3.35
Bid: 3.30
Ask: 3.40
Change: 0.05 (1.52%)
Spread: 0.10 (3.03%)
Open: 3.30
High: 3.35
Low: 3.30
Prev. Close: 3.30
VAL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

3 Aug 2020 14:49

RNS Number : 9761U
ValiRx PLC
03 August 2020
 

TR-1: Standard form for notification of major holdings

 

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii:

Valirx PLC

1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)

Non-UK issuer

2. Reason for the notification (please mark the appropriate box or boxes with an "X")

An acquisition or disposal of voting rights

X

An acquisition or disposal of financial instruments

An event changing the breakdown of voting rights

Other (please specify)iii:

3. Details of person subject to the notification obligationiv

Name

Monecor (London) Limited

City and country of registered office (if applicable)

London, UK

4. Full name of shareholder(s) (if different from 3.)v

Name

City and country of registered office (if applicable)

5. Date on which the threshold was crossed or reachedvi:

31/07/2020

6. Date on which issuer notified (DD/MM/YYYY):

03/08/2020

7. Total positions of person(s) subject to the notification obligation

% of voting rights attached to shares (total of 8. A)

% of voting rights through financial instruments(total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights of issuervii

Resulting situation on the date on which threshold was crossed or reached

6.413

-

6.413

54,062,373

Position of previous notification (if

applicable)

8.86

8.86

 

8. Notified details of the resulting situation on the date on which the threshold was crossed or reachedviii

A: Voting rights attached to shares

Class/type ofshares

ISIN code (if possible)

Number of voting rightsix

% of voting rights

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

Ordinary Shares

GB00BLH13C52

 

3,466,989

-

6.413

-

SUBTOTAL 8. A

3,466,989

6.413

 

 

B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))

Type of financial instrument

Expirationdatex

Exercise/Conversion Periodxi

Number of voting rights that may be acquired if the instrument is

exercised/converted.

% of voting rights

SUBTOTAL 8. B 1

 

 

B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))

Type of financial instrument

Expirationdatex

Exercise/Conversion Period xi

Physical or cash

settlementxii

Number of voting rights

% of voting rights

SUBTOTAL 8.B.2

 

 

 

 

9. Information in relation to the person subject to the notification obligation (please mark the

applicable box with an "X")

Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuerxiii

X

Full chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entityxiv (please add additional rows as necessary)

Namexv

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

10. In case of proxy voting, please identify:

Name of the proxy holder

The number and % of voting rights held

The date until which the voting rights will be held

11. Additional informationxvi

 

Place of completion

London, UK

Date of completion

03/08/2020

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
HOLUOSORRWUWRAR
Date   Source Headline
17th Oct 20187:00 amRNSVAL201 in concluding stages of Phase I/II trial
15th Oct 201812:00 pmRNSVAL401 results shortly to be on ClinicalTrials.gov
25th Sep 20187:00 amRNSHalf-year Report
14th Sep 201812:42 pmRNSIssue of Equity
6th Sep 20187:00 amRNSUpdate on Clinical Development
24th Jul 201812:17 pmRNSResult of General Meeting
17th Jul 20187:00 amRNSUS PATENT GRANT FOR THERAPEUTIC COMPOUND, VAL301
6th Jul 20184:42 pmRNSNotice of GM
14th Jun 20187:00 amRNSVAL401 Update
24th May 20189:00 amRNSPrice Monitoring Extension
11th May 20182:56 pmRNSHolding(s) in Company
8th May 201812:13 pmRNSResult of AGM
4th May 20184:40 pmRNSSecond Price Monitoring Extn
4th May 20184:35 pmRNSPrice Monitoring Extension
4th May 20184:01 pmRNSPlacing and grant of warrants
26th Apr 20182:05 pmRNSSecond Price Monitoring Extn
26th Apr 20182:00 pmRNSPrice Monitoring Extension
25th Apr 20184:40 pmRNSSecond Price Monitoring Extn
25th Apr 20184:35 pmRNSPrice Monitoring Extension
25th Apr 20187:00 amRNSEU Patent Grant for Therapeutic Compound, VAL201
20th Apr 201810:45 amEQSHardman & Co Research: ValiRx (VAL): 2017: a pivotal year
19th Apr 20187:00 amRNSGENEICE & VAL101 Update
12th Apr 20187:00 amRNSNotice of AGM
10th Apr 20187:00 amRNSFinal Results
20th Mar 20187:00 amRNSUS Patent Grant for Therapeutic Compound, VAL201
19th Mar 20187:00 amRNSHolding(s) in Company
16th Mar 20183:01 pmRNSAppointment of Broker
2nd Mar 201811:01 amRNSStatement re broker
9th Feb 201811:57 amRNSIssue of options and directors dealings
2nd Feb 20184:26 pmRNSHolding(s) in Company
25th Jan 201812:06 pmRNSHolding(s) in Company
23rd Jan 20183:30 pmRNSHolding(s) in Company
16th Jan 20187:00 amRNSValiSeek Clinical Update (VAL401)
11th Jan 20187:00 amRNSUS Patent Notice of Allowance for Compound VAL201
4th Jan 20182:29 pmRNSHolding(s) in Company
3rd Jan 20187:00 amRNSExercise of Warrants and Issue of Equity
27th Dec 201712:54 pmRNSFinal Loan Note Conversion and Issue of Equity
22nd Dec 20177:00 amRNSIssue of Equity
21st Dec 20179:16 amRNSResult of General Meeting
20th Dec 20173:58 pmRNSWarrant Exercise
20th Dec 20173:03 pmRNSWarrant Exercise
18th Dec 20178:45 amRNSWarrant Exercise
18th Dec 20177:00 amRNSre: VAL201 Clinical Trials
15th Dec 20177:00 amRNSExercise of Warrants and Issue of Equity
12th Dec 20177:00 amRNSValiSeek Clinical Development Update
11th Dec 20173:48 pmRNSLoan Note Conversion and Issue of Equity
6th Dec 20177:00 amRNSShareholder Circular and Notice of General Meeting
30th Nov 20172:38 pmRNSIssue of Equity
20th Nov 201711:23 amRNSHolding(s) in Company
15th Nov 20174:37 pmRNSYorkville CLN Conversion

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.